These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 6896620)

  • 1. [Use of plasmapheresis in a case of Graves' disease with malignant ophthalmopathy (author's transl)].
    Glinoer D; Gaham N; Sand G; Libert J; Grivegnee A; Badjou R; Ermans AM
    Ann Endocrinol (Paris); 1981 Dec; 42(6):545-6. PubMed ID: 6896620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Graves' ophthalmopathy by steroid therapy, orbital radiation therapy, plasmapheresis and thyroxine replacement.
    Yamamoto K; Saito K; Takai T; Yoshida S
    Endocrinol Jpn; 1982 Aug; 29(4):495-501. PubMed ID: 6897533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of intensive plasma exchange followed by immunosuppressive therapy in severe Graves' ophthalmopathy.
    Glinoer D; Etienne-Decerf J; Schrooyen M; Sand G; Hoyoux P; Mahieu P; Winand R
    Metab Pediatr Syst Ophthalmol (1985); 1988; 11(3):133-40. PubMed ID: 3205168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effects of intensive plasma exchange followed by immunosuppressive therapy in severe Graves' ophthalmopathy.
    Glinoer D; Etienne-Decerf J; Schrooyen M; Sand G; Hoyoux P; Mahieu P; Winand R
    Acta Endocrinol (Copenh); 1986 Jan; 111(1):30-8. PubMed ID: 2868602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of patients with Graves' orbitopathy treated by plasmapheresis and immunosuppression.
    Zielinski CC; Weissel M; Müller C; Till P; Höfer R
    Dev Ophthalmol; 1989; 20():130-8. PubMed ID: 2574116
    [No Abstract]   [Full Text] [Related]  

  • 6. Enhanced prednisolone elimination: a possible cause for failure of glucocorticoid therapy in Graves' ophthalmopathy.
    Legler UF
    Horm Metab Res; 1987 Apr; 19(4):168-70. PubMed ID: 3583222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Results of 3-stage treatment: (I) corticotherapy, (II) linear acceleration and (III) orbital decompression in 206 patients with malignant Graves ophthalmopathy].
    Zgliczyński S; Jastrzebska H; Górowski T; Janik J; Kuś J; Hliniak A; Karczmarzyk R; Kukołowicz P
    Endokrynol Pol; 1992; 43(3):274-86. PubMed ID: 1345567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma exchange therapy for severe Graves' ophthalmopathy.
    Glinoer D; Schrooyen M; Winand R
    Dev Ophthalmol; 1989; 20():91-3. PubMed ID: 2591631
    [No Abstract]   [Full Text] [Related]  

  • 9. [Analysis of early and late results of progressive Graves-Basedow ophthalmopathy treatment with different methods].
    Pilarska K; Czekalski S; Syrenicz A; Andrzejewska W; Krzystolik Z; Przerwa D
    Pol Tyg Lek; 1992 Nov 2-9; 47(44-45):1000-3. PubMed ID: 1305709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.
    Prummel MF; Wiersinga WM; Mourits MP; Koornneef L; Berghout A; van der Gaag R
    Arch Intern Med; 1990 May; 150(5):1098-101. PubMed ID: 1691908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group.
    Tallstedt L; Lundell G; Tørring O; Wallin G; Ljunggren JG; Blomgren H; Taube A
    N Engl J Med; 1992 Jun; 326(26):1733-8. PubMed ID: 1489388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma exchange therapy for severe Graves' ophthalmopathy.
    Glinoer D; Schrooyen M
    Horm Res; 1987; 26(1-4):184-9. PubMed ID: 3596467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of plasmapheresis in Graves' ophthalmopathy.
    Glinoer D
    Exp Clin Endocrinol; 1991 May; 97(2-3):328-31. PubMed ID: 1915651
    [No Abstract]   [Full Text] [Related]  

  • 14. [Therapy for Graves' ophthalmopathy].
    Zheng J; Zhang X; Gong R; Wang J; Tan T
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2004 Oct; 21(5):876-9. PubMed ID: 15553880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic management of dysthyroid ophthalmopathy.
    Fells P
    Eye (Lond); 1988; 2 ( Pt 2)():198-200. PubMed ID: 3058526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism.
    Marcocci C; Bartalena L; Bogazzi F; Bruno-Bossio G; Pinchera A
    Thyroid; 1992; 2(2):171-8. PubMed ID: 1525588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of plasma exchange for Graves' ophthalmopathy.
    Kelly W; Longson D; Smithard D; Fawcitt R; Wensley R; Noble J; Keeley J
    Clin Endocrinol (Oxf); 1983 May; 18(5):485-93. PubMed ID: 6688205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy.
    Kahaly G; Pitz S; Müller-Forell W; Hommel G
    Clin Exp Immunol; 1996 Nov; 106(2):197-202. PubMed ID: 8918563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis of exophthalmos using orbital ultrasonography and treatment of malignant exophthalmos with steroid therapy, orbital radiation therapy, and plasmapheresis.
    Yamamoto K; Saito K; Takai T; Yoshida S
    Prog Clin Biol Res; 1983; 116():189-205. PubMed ID: 6134291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylprednisolone increases plasma leptin levels in Graves' hyperthyroidism patients with active Graves' ophthalmopathy.
    Song YM; Lee WJ; Chen MD; Kao CH; Sheu WH
    Horm Metab Res; 2000 Jul; 32(7):277-82. PubMed ID: 10965934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.